Table 3.

Quantile Regression of 1- and 5-Year Change in Height SDS (∆HtSDS) and Height in SD Units From the Mean for Age (HtSDS) at 5 Years of GH Therapy, for Childhood Cancer Survivors With and Without Irradiation in GH-Treated Cancer Survivors With GH Deficiency Entered in the KIGS Database, Quantile 0.50 (median)

Exploratory Variable	1-Year ΔHtSDS		5-Year ΔHtSDS		HtSDS at 5 Years of GH
	Estimate	P Value	Estimate	P Value	Estimate	P Value
Craniopharyngioma (RT)	0.75	<0.0001	2.24	<0.0001	-0.17	0.47
Craniopharyngioma (no RT)	0.80	<0.0001	2.25	<0.0001	-0.23	0.32
Leukemia (TBI)	0.27	0.015	0.90	0.0004	-1.74	<0.001
Leukemia (no TBI)	0.50	0.0001	1.69	<0.0001	-0.77	0.002
Medulloblastoma	0.47	<0.0001	1.48	<0.0001	-1.02	<0.001
Craniopharyngioma RT vs craniopharyngioma no RT	-0.05	0.47	-0.01	0.96	0.05	0.68
Craniopharyngioma RT vs leukemia (TBI)	0.48	<0.0001	1.34	<0.0001	1.56	<0.001
Craniopharyngioma RT vs leukemia (no TBI)	0.25	0.012	0.56	0.0004	0.59	<0.001
Craniopharyngioma RT vs medulloblastoma	0.28	<0.0001	0.76	<0.0001	0.85	<0.001
Craniopharyngioma no RT vs leukemia (TBI)	0.53	<0.0001	1.35	<0.0001	1.51	<0.001
Craniopharyngioma no RT vs leukemia (no TBI)	0.30	0.003	0.56	0.0004	0.54	<0.001
Craniopharyngioma no RT vs medulloblastoma	0.33	<0.0001	0.76	<0.0001	0.79	<0.001
Leukemia (TBI) vs leukemia (no TBI)	-0.23	0.011	-0.79	<0.0001	-0.97	<0.001
Leukemia (TBI) vs medulloblastoma	-0.20	<.0001	-0.58	<0.0001	-0.72	<0.001
Leukemia (no TBI) vs medulloblastoma	0.03	0.72	0.21	0.15	0.25	0.018
In puberty	0.57	<.0001	1.84	<0.0001	-0.56	0.019
Prepubertal	0.55	<.0001	1.58	<0.0001	-1.01	<0.001
In puberty vs prepubertal	0.02	0.70	0.26	0.024	0.45	<0.001
Age at GHT start (y)	-0.04	0.0003	-0.07	<0.0001	-0.06	0.002
Weight (SDS) at GHT start	0.04	0.003	0.07	0.39	NA
Dose at GHT start (mg/kg/wk)	1.56	<0.0001	1.68	0.014	2.36	<0.001

Values shown are parameter estimates and P values from quantile regression at the 50th percentile.

Abbreviations: GHT, GH therapy; RT, radiotherapy; SDS, SD score; TBI, total body irradiation.